Skip to content
Bone Wizardry
Lynch syndrome: from tumor mismatch repair to prevention

GI

Lynch syndrome: from tumor mismatch repair to prevention

The tumor raises the flag; germline testing establishes the inherited diagnosis.

Primary diagnostic image
Lynch syndrome accelerates carcinoma through mismatch-repair failure, often with relatively few precursor polyps.Netha Hussain / Wikimedia Commons (CC BY-SA 3.0). Source CC BY-SA 3.0
  • Connect MLH1, MSH2, MSH6, PMS2, and EPCAM alterations to mismatch-repair deficiency and microsatellite instability.
  • Interpret universal colorectal and endometrial tumor screening as a triage pathway rather than a germline diagnosis.
  • Apply colonoscopic, gynecologic, and selected extracolonic surveillance and prevention for confirmed Lynch syndrome.

Progression ladder

Follow progression from driver to treatment

The figure separates tumor initiation, progression, staging, and treatment decisions.

Quick check

A 43-year-old with right-sided colon cancer has tumor immunohistochemistry showing loss of MSH2 and MSH6 with retained MLH1 and PMS2. His mother had endometrial cancer at 47.

What is the most appropriate next step?

Recall the Lynch cancer spectrum

Right-sided colorectal and endometrial cancers are the anchors, not the limits.

Lynch syndrome increases risk for colorectal, endometrial, ovarian, gastric, small-bowel, biliary tract, pancreatic, upper urinary tract, brain, and sebaceous skin tumors.

The magnitude and age of risk vary by gene: MLH1 and MSH2 generally carry higher colorectal risk, while MSH6 and PMS2 often have later or lower penetrance for some cancers.

Select the cancer cluster most characteristic of Lynch syndrome.

A right-sided colon cancer plus an early endometrial cancer in the pedigree should make mismatch repair the first molecular language considered.

Follow universal tumor screening to germline confirmation

Universal screening finds patients whose age and pedigree alone would miss the diagnosis.

Screen newly diagnosed colorectal and endometrial cancers with mismatch-repair immunohistochemistry, microsatellite instability testing, or a validated tumor sequencing pathway.

Use the protein pattern to select reflex testing. MLH1/PMS2 loss prompts MLH1 methylation assessment and, for colorectal cancer, often BRAF testing; unexplained deficient repair then proceeds to genetics and germline testing.

Put the diagnostic pathway in order.

  1. Screen the tumorPerform MMR immunohistochemistry, MSI testing, or a validated equivalent on colorectal and endometrial cancers.

Compare mismatch-repair gene patterns

The lost protein pair narrows the next test because mismatch-repair proteins work as partners.

MLH1 pairs with PMS2, and MSH2 pairs with MSH6. Loss of a core partner often causes paired loss; isolated PMS2 or MSH6 loss more directly points to that gene.

EPCAM deletions can epigenetically silence neighboring MSH2. MLH1 loss requires special attention because sporadic MLH1 promoter methylation is common in colorectal and endometrial cancer.

Match the tumor pattern to its leading interpretation.

Evaluate for sporadic MLH1 promoter methylation; in colorectal cancer, BRAF V600E can also support a sporadic pathway before germline MLH1 testing.

Deficient mismatch repair and MSI-high are tumor phenotypes; Lynch syndrome is the inherited cause in only a subset of those tumors.

Map surveillance to the organs at risk

Colonoscopy is the most proven surveillance tool, while extracolonic screening is selected by sex, gene, family history, and guideline.

Colon cancers often arise proximally and can develop faster than sporadic adenoma-carcinoma progression, supporting frequent complete colonoscopy rather than sigmoidoscopy.

Endometrial and ovarian prevention requires symptom education and individualized screening or surgery. Gastric, urinary-tract, pancreatic, brain, and skin strategies depend more heavily on family history and risk context.

Map each organ to the appropriate prevention concept.

Anchor surveillance to age and interval

Lynch surveillance is earlier and more frequent than average-risk colorectal screening.

For many MLH1 or MSH2 carriers, colonoscopy begins at age 20 to 25 years and repeats every 1 to 2 years. A family cancer before that window can move the start 2 to 5 years earlier than the youngest diagnosis.

Upper endoscopy and urinary surveillance are considered around age 30 to 35 years in selected higher-risk patients; these are not substitutes for colonoscopy.

Place major Lynch surveillance landmarks on the age axis.

Total: 0

Open prevention from colonoscopy to risk-reducing surgery

Prevention is layered: remove precursors, treat cancers appropriately, reduce selected organ risk, and test relatives.

Confirmed carriers generally receive colonoscopy every 1 to 2 years beginning at age 20 to 25 years or 2 to 5 years before the earliest family colorectal cancer; gene-specific guidance may start MSH6 and PMS2 later.

Aspirin can reduce colorectal cancer risk and should be discussed using current dose, bleeding risk, and comorbidity guidance. Risk-reducing hysterectomy and bilateral salpingo-oophorectomy are considered after childbearing, with gene-specific ovarian risk informing the decision.

Reveal what each prevention layer actually accomplishes.

Frequent complete colonoscopy

Detects and removes precursors and early cancers across the proximal and distal colon.

Continue after segmental colectomy because metachronous colorectal risk remains.

Cancer surgery

Choose segmental versus extended colectomy by tumor, age, gene, function, and metachronous risk.

A Lynch diagnosis informs the extent but does not replace patient-centered surgical judgment.

Gynecologic risk reduction

Offer hysterectomy after childbearing and individualize oophorectomy by gene, age, menopause, and patient priorities.

Screening has less evidence for mortality reduction than definitive risk-reducing surgery.

Aspirin and cascade testing

Discuss aspirin chemoprevention and test first-degree relatives for the confirmed familial variant.

Relatives who test negative for that variant can usually return to risk-appropriate population screening.

Universal tumor testing finds the door; germline confirmation decides who in the family should walk through it.

Stage 1 of 3: Overview

Overview

Lynch syndrome: from tumor mismatch repair to prevention

Universal screening finds patients whose age and pedigree alone would miss the diagnosis.

Work through the oncology pathway

Five tumor and family-history patterns test whether screening, reflex testing, germline confirmation, and prevention stay in the correct order.

Cross out stage mismatches and highlight the treatment-changing clue. Each case separates biology, stage, and intent.

A 44-year-old with ascending-colon cancer has loss of MSH2 and MSH6 on immunohistochemistry. His mother had endometrial cancer and his maternal uncle had ureter cancer.

Which test best advances the inherited diagnosis?

Tumor-board pivot

Choose the finding that changes the pathway

Choose the feature that changes diagnosis, stage, or treatment intent.

What is the most appropriate next step?

Rapid review

Three questions to check

What is the most appropriate next step?

Obtain genetics evaluation and germline testing focused on MSH2/EPCAM and the mismatch-repair panel. MSH2 loss destabilizes MSH6; germline confirmation distinguishes inherited Lynch syndrome from a tumor-only event.

Which heterodimer is absent?

MSH2-MSH6.

Which family tumors reinforce Lynch syndrome?

Endometrial and upper urinary tract cancers.

Related GI topics

GIColorectal Cancer: Find It, Stage It, Treat ItLaterality changes the first clue, but tissue diagnosis and anatomic stage determine the next move.GIHereditary polyposis syndromes: gene, polyp, phenotypeThe inheritance pattern narrows the gene; the polyp histology narrows the syndrome; the extracolonic findings close the loop.GIMalabsorption SyndromesSeparate failed digestion from damaged mucosa and isolated brush-border enzyme loss.

Medically reviewed

Fatima Ali, DO

Fatima Ali, DO

PGY-1 Resident Physician in Psychiatry

University Hospitals, Columbia

DO from Kansas City University

Resident physician and founding medical reviewer at Bone Wizardry, focused on clinical accuracy, clear diagnostic reasoning, and practical board-oriented teaching across the curriculum.

Languages: English, Urdu

Primary reviewerFull physician profile

Medically reviewed

Sources

  1. Lynch Syndrome2021

Bone Wizardry is a study resource for medical students. It is not medical advice.